HC Wainwright Issues Negative Forecast for CervoMed Earnings

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at HC Wainwright decreased their Q1 2026 EPS estimates for CervoMed in a report issued on Tuesday, March 17th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.92) per share for the quarter, down from their previous forecast of ($0.86). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. HC Wainwright also issued estimates for CervoMed’s Q2 2026 earnings at ($0.70) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.71) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.53) EPS, Q3 2027 earnings at ($0.57) EPS and Q4 2027 earnings at ($0.62) EPS.

CRVO has been the subject of several other reports. D. Boral Capital restated a “buy” rating and issued a $31.00 price objective on shares of CervoMed in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, January 21st. Zacks Research raised CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Cantor Fitzgerald began coverage on CervoMed in a research note on Thursday, December 18th. They issued an “overweight” rating for the company. Finally, Roth Mkm dropped their price target on CervoMed from $19.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

CervoMed Price Performance

Shares of NASDAQ CRVO opened at $4.24 on Thursday. CervoMed has a 1 year low of $3.58 and a 1 year high of $16.94. The stock has a market capitalization of $39.26 million, a P/E ratio of -1.42 and a beta of -0.77. The company’s 50-day moving average is $5.28 and its 200 day moving average is $7.21.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings data on Friday, March 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.09). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.84 million. CervoMed had a negative return on equity of 96.04% and a negative net margin of 672.80%.

Institutional Investors Weigh In On CervoMed

Several hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new position in shares of CervoMed during the fourth quarter valued at approximately $88,000. XTX Topco Ltd purchased a new position in shares of CervoMed during the fourth quarter valued at approximately $81,000. Marshall Wace LLP bought a new stake in shares of CervoMed in the 2nd quarter worth approximately $76,000. Rhumbline Advisers grew its stake in shares of CervoMed by 35.5% in the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of CervoMed by 8,425,900.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock worth $666,000 after buying an additional 84,259 shares during the last quarter. Institutional investors own 25.15% of the company’s stock.

CervoMed News Summary

Here are the key news stories impacting CervoMed this week:

• Positive Sentiment: Positive Phase 2b RewinD‑LB results and regulatory alignment: CervoMed reported clinically meaningful Phase 2b data in dementia with Lewy bodies (DLB), obtained FDA and other regulator alignment on a planned global Phase 3 (≈300 patients) and selected the Phase 3 dose/formulation — a clear clinical catalyst if funding is secured. GlobeNewswire Release
• Positive Sentiment: HC Wainwright reiterates Buy and raised some EPS forecasts: HC Wainwright keeps a Buy rating and $25 target while updating quarterly and FY estimates (including an improved FY2026 loss estimate), reinforcing analyst support ahead of Phase‑3 planning. MarketBeat HC Wainwright Note
• Positive Sentiment: Additional analyst support: Chardan Capital raised its price target to $21 (Buy), which adds to upside narratives and widens the range of bullish targets. TickerReport / Benzinga
• Positive Sentiment: Insider buying and selective institutional buying: Company insiders have reported multiple purchases recently; some institutions added shares in Q4 2025 — a signal of insider confidence that may support sentiment. Quiver Quant Summary
• Neutral Sentiment: Other buy ratings: D. Boral Capital and Cantor Fitzgerald also have positive stances, contributing to a consensus skewed to Buy but with widely dispersed targets (median target cited ~$25). American Banking News
• Negative Sentiment: Cash runway and widening losses: Q4/2025 results show cash fell to ~$20.9M (≈ six months runway at current plan) and net loss widened to ≈$27M — funding needs for Phase 3 are material and could mean dilution or financing risk. GlobeNewswire Release
• Negative Sentiment: Mixed analyst moves — some cuts: Roth MKM cut its price target to $11 (from $19) despite a Buy rating, highlighting divergence among analysts on valuation and raising near‑term downside risk if funding or trial execution concerns grow. Benzinga

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.